Keyphrases
Chronic Kidney Disease
100%
Core Outcome Set
100%
Randomized Controlled Trial
66%
Clinical Trials
60%
Sorafenib
33%
Risk Outcomes
33%
Patient Outcomes
33%
Risk-benefit
33%
Patient Benefit
33%
Drug Development
33%
Web-based Survey
33%
Clinical Perspective
33%
Patient Risk
33%
Sectional Analysis
33%
FDA-approved Drugs
14%
Off-label Indications
14%
Literature Search
12%
Data Extraction
12%
Trialists
12%
International Consortium
12%
Health Measurement
12%
Health-related Quality of Life
12%
Health Outcomes
12%
Adverse Events
9%
Approved Indication
9%
Monotherapy
9%
Objective Response Rate
9%
Progressive Conditions
7%
Patient-reported Health
7%
Modality-specific
7%
Treatment Quality
7%
Treatment Modalities
7%
Disease Burden
7%
Disease Research
7%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Clinical Trial
67%
Randomized Controlled Trial
66%
Sorafenib
33%
Drug Development
33%
Cross Sectional Study
33%
Adverse Event
14%
Malignant Neoplasm
14%
Monotherapy
9%
Diseases
5%
Medicine and Dentistry
Chronic Kidney Disease
100%
Clinical Trial
67%
Randomized Controlled Trial
66%
Sorafenib
33%
Cross Sectional Study
33%
Health Outcomes
15%
Quality of Life
15%
Adverse Event
14%
Malignant Neoplasm
9%
Monotherapy
9%
Diseases
5%